News, trends, and stories from the synthetic biology industry
Hi , Today is the day! Our Biopharma event starts at 8am PST. You still have a chance to join and be a part of the conversations that are shaping the future of biopharma in a post-COVID world. Click here and join the event now! Early Bird Tickets Launch Next Week!
We’ve also negotiated a special deal with the Oakland Marriott City Center so that your networking can start early and end late. There are a limited number of discounted rooms available so we suggest booking your room ASAP! Click here to make your reservation.
The Built with Biology Clubhouse is moving to Twitter Spaces!
Thank you to everyone who has sent us feedback about Clubhouse. We’ve heard that the
platform isn’t accessible enough that it’s limited to those who can get an invite. We want to build an inclusive community, not an exclusive one. So next week, we’re moving the show to Twitter Spaces!
After our Biopharma event, our Built with Biology show on Wednesday, June 2nd will be on Spaces. Spaces is also an audio-only platform but all you need is a Twitter handle and the Twitter app on your phone. Click here to save next week's show on your phone!
Next week, we’re excited to welcome to the show:
Helene Steiner, CEO of Open Cell London, an organization that builds modular labs in shipping containers to make prototyping tools and discovery space more accessible and affordable for biotech startups.
The Search for a Cancer Vaccine: Have We Been Doing It All Wrong? For nearly 250 years, scientists have attempted to rid the world of one of its most pervasive and horrible diseases—cancer. And, for at least the past 150 years, there have been repeated efforts to create a vaccine that might prevent, treat, or even cure it. We have all kinds of vaccines today, including the previously elusive mRNA vaccines. So, why don’t we have a cancer vaccine?
John Cumbers for Forbes
This Company Is Freeing Manufacturers From Petrochemicals With Biology Today, entire industries still depend on fossil fuels and their derivative materials, petrochemicals. But the clean energy and sustainable products movement is starting to change how companies source their raw materials. Now, bioengineering startup Origin.Bio plans to free manufacturers from their petrochemical dependency by co-designing with nature to create more sustainable products.
Building a New Era of Biotechnology Through Collaboration We have entered a new era of biotechnology where collaboration is the key to success. By breaking down silos across the industry, we are advancing science and making it more accessible. A new partnership between Berkeley Lights, a digital cell biology company, and Genovac, an antibody discovery company, exemplifies how industry collaboration can find elusive answers to some of the biggest problems in antibody therapy.
Science News
Cultivated meat likely to make up 40% of future meat intake: A new study suggests that cultivated meat is likely to be widely accepted by the general public, especially the younger generations and an eager group of early adopters who appreciate its benefits across a wide range of social issues.
The biosciences, including biotechnology, will play a pivotal role in the fight against climate change. It is already leading the way on several fronts, writes Michelle McMurry-Heath, the president and CEO of the Biotechnology Innovation Organization.
The biorevolution is kicking off. Its potential cannot be reached without global collaboration, including at a political level. Regulation is
desperately required to both allow for and speed up scientific progress in this area.
Funding News
Eat Just, a San Francisco-based maker of plant-based egg products, raised $170 million in new funding to help expand its cell-based meat subsidiary, GOOD Meat.
According to a BCG report, it is not yet clear which new deep tech ventures are most likely to succeed, which investments will yield the greatest returns, or how rapidly their promise will be realized. But
the field is already accelerating more quickly than many experts expected. Read about the deep tech investment paradox.
